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The completion of the human genome is a
major achievement of the 20th century.
The 21st century challenge is to determine
the function of the many newly discovered
genes and how their gene products interact
in pathways and systems to create the
human body. An important approach in
meeting this challenge in functional
genomics is the use of large-scale analyses
of the transcriptome and proteome. The
human proteome is derived from the gene
expression particular to a cell or tissue
involving the dynamic and coordinated
interaction of proteins in the body.
“Mapping the human proteome” (Maher
2002) or describing the complex nature of
protein structures, actions, and organiza-
tional hierarchies will be very unlike, and
much more complex than, mapping the
DNA sequence of the human genome.
Multiple technologies and international
cooperative strategies are being planned to
meet the challenge of defining the human
proteome and the subtle genetic variations
reflected in protein polymorphisms that
define each individual. This article sum-
marizes proceedings of a new proteomics
organization, comments on its goals and
directions for the field of proteomics, and
demonstrates why environmental health
researchers have a vested interest in the
agenda, cooperative studies, and shared
resources that will emanate from this
organization’s activities. 
The Human Proteome Organization,
HUPO (2002), held an international
meeting and workshop at the National
Institutes of Health on 29 April 2002 to
prioritize goals and standards for large-scale
analysis of the human proteome. The mis-
sion of the organization is to consolidate
national proteome organizations into the
international body HUPO; to engage in sci-
entific and educational activities that pro-
mote technologies pertaining to the human
proteome and model organisms; and to
assist in coordinating shared, public pro-
teomic initiatives. The president of the
organization is Samir E. Hanash at the
University of Michigan. Currently, mem-
ber countries are linked by three interna-
tional HUPO divisions: North America,
Europe, and Asia–Oceania, with countries
from all three divisions participating at the
workshop. The two major challenges for
HUPO are to identify major opportunies
first for international cooperation and sec-
ond for joint initiatives between public and
private sectors. 
The HUPO meeting focused on
developing specific agendas in five key
areas (Figure 1) of human proteomics for
immediate international development,
chaired by recognized leaders in the
field: “Bioinformatics,” Rolf Apweiler
(University of Heidelberg, Heidelberg,
Germany; EMBL, European Bioinformatic
Institute, Hinxton, Cambridge, UK);
“New Technology,” Richard Simpson
(Ludwig Institute, Melbourne, Victoria,
Australia); the “Plasma Proteome,” Gilbert
S. Omenn (University of Michigan, Ann
Arbor, Michigan, USA); “Cell Models and
Tissues,” Ronald Taussig (University of
Michigan), Cell Signaling Alliance and
Pei Pei Ping (University of California,
Los Angeles, California, USA); and the
“Antibody Initiative,” Mattihias Mann
(Odense University, Odense, Denmark). A
brief discussion of each area follows.
Bioinformatics
The bioinformatics group will define the
proteomic data platforms such as 2D (two-
dimensional) gels, protein arrays, mass spec-
trometry, and structural data into a deﬁned
infrastructure for data submission and
annotation. A major bioinformatics issue is
to determine a direction toward either a
linked, interoperable consortium of small
distributed proteomics databases or the
alternative of a large, centralized database.
Annotation standards need to be defined
using a controlled vocabulary and data con-
ﬁdence measures. Because journals contain
many raw and processed proteomic data for
potential database incorporation, copyright
and accessibility issues need to be resolved. 
New Technology
The new technology group had several
objectives that included determining lead
technologies for best discovering protein
interactions, quantifying proteins over a
wide dynamic range, fractionating cellular
and subcellular compartments to accept-
able levels of purity, and identifying house-
keeping genes for normalization. The
group plans to establish web-based HUPO
protocols and make available sets of protein
standards that are platform-independent.
The group was interested in whether
high throughput technologies could be
developed to define protein states such as
posttranslational modiﬁcations, protein con-
formations, cellular localization, splice vari-
ants, covalent modifications, proteoloysis,
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The Human Proteome Organization, or HUPO, was formed to promote research and large-scale
analysis of the human proteome. By consolidating national proteome organizations into an inter-
national body, HUPO will coordinate international initiatives, biological resources, protocols,
standards and data for studying the human proteome. HUPO has identified five key areas to
advance study of the human proteome, specifically in bioinformatics, new technologies, the
plasma proteome, cell models, and a public antibody initiative. Consideration of three major issue
areas may help develop HUPO’s strategy for human proteome study. First is the need to distin-
guish the value of high throughput platforms from discovery platforms in proteomics. Second is
the importance for international planning on integrating both transcriptome and proteome data
and databases. Last is that effects of the environment from chemical, physical, and biological
exposures alter the expression and structure of the proteome, which become manifest in long-
term adverse health effects and disease. Environmental health research stands to greatly benefit
from the shared resources, data, and vision of the HUPO organization as a valuable resource in
exploiting knowledge of the human proteome toward improving public health. Key words: envi-
ronmental health, bioinformatics, human, proteome, proteomics, toxicogenomics, toxicology,
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5,000 proteins from a speciﬁc cell or tissue
type to generate an enriched dataset useful
for future studies. 
Plasma Proteome
The plasma proteome section discussed
plans for a comprehensive proteomic analy-
sis of human plasma constituents in the
general population and identiﬁcation of the
major sources of variation in the plasma
proteome such as age, nutrition, gender,
menstrual cycle, exercise, medication, and
disease state. There was much discussion
about formulating a pooled, multiethnic
“reference sample” of plasma or serum to be
shared among participating laboratories.
Because only a few hundred soluble blood
proteins are known, the group plans to
more completely identify and catalog
plasma proteins with future plans for a
plasma proteome database. An informal
poll among participants showed a prefer-
ence of serum over plasma for proteomic
analysis. A number of issues were identiﬁed,
including genetic variation of plasma pro-
teins, liquid-phase multidimensional sepa-
ration schemes compared with gel-based
separation methods, parameters for high
throughput links to mass spectrometry
(MS), removal of high abundance proteins,
and use of antibody arrays or multiplexed
enzyme-linked immunosorbent assays
(ELISAs) for plasma protein analysis. The
question of using pooled or individual
plasma samples was raised, as well as the
desirability of animal models to help sort
the factors accounting for variations in the
plasma proteome.
Cell Models and Tissue
The cell models group plans to develop
criteria for “attractive” cell and tissue sys-
tems that would be widely recognized as a
reference type and to recommend specific
pilot studies for construction of a cellular
proteomic database. Criteria discussed
for model cells/tissues included specific
organs, amenability to functional assays,
high interest to biology or medicine,
availability of biological material and
funding resources, and ease of identifying
proteins. Some participants commented
that standardizing protocols might be difﬁ-
cult in a research setting but could be pro-
moted by an international body like
HUPO. Existing DNA and protein data-
bases for many nonhuman models were
discussed as incomplete, which might make
such species less desirable for model adop-
tion. The merits of primary cells were com-
pared with those of immortalized cell lines
and stem cells. Also considered was the
possibility that several cells or organs might
have to serve as models because of the wide
range of participant interests. Overall, there
was strong sentiment that choice of model
and of pilot studies should be a biologically
driven decision rather than a technology-
driven exercise. 
Antibody Initiative
The HUPO antibody initiative gained
considerable attention at the workshop
because of the pervasive use of antibodies
in biological research, the duplication of
effort in making antibodies at commercial
and research sources, a growing need for a
standardized, public antibody collection
characterized by application for use, and a
widespread desire for developing antibody
arrays (Borrebaeck et al. 2001), multi-
plexed ELISA (Moody et al. 2001), and
microfluidic antibody systems (Walter et
al. 2002). The intent of such a public anti-
body collection would be to develop high-
quality antibodies for every human protein,
with distribution to researchers at a mini-
mal cost. The creation of antibodies was
discussed as an internationally funded
effort that would likely use bioinformati-
cally chosen peptide antigens to produce
polyclonal antibodies as a relatively rapid
and inexpensive means to produce a high-
affinity product. Selection of the animal
host required further discussion ranging
from using avian species for noninvasive
and high-efficiency collection of IgY anti-
bodies (chicken immunoglobulin derived
from the egg yolk) (Tini et al. 2002) to
more traditional mammalian species such
as rabbit. 
Members of HUPO fundamentally
agree that describing the human proteome
will be vastly more complex than the
Human Genome Project but can greatly
benefit the scientific community from a
cooperative international effort with shared
public resources, tools, and data. Each of
the five working groups was challenged to
identify specific milestones and objectives
to be eventually set forth by the leadership
of each group. As group agendas become
more reﬁned by HUPO, three major issues
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Figure 1. HUPO has developed an agenda in ﬁve key areas for international proteomic research. See text
for details.were identiﬁed that should be articulated in
the mapping of the human proteome.
Platforms for Discovery and
High Information Density
in Proteomics
A major goal of HUPO is the mapping of
5000 human proteins. Mapping the
human proteome is well recognized as an
imperfect analogy drawn from the human
genome’s assembling of DNA sequences.
Yet, a description or map of changing levels
of all cellular transcripts and gene products
over time under a variety of conditions is
an important functional approach to derive
meaning from the genome. In this regard, a
prime advantage of DNA microarray tech-
nology is the relatively large volume of
transcript information gained from a single
analysis, which could be viewed as a “high
information density” technology. The
starting source of biological material for
microarray studies, RNA, is the same
regardless of tissue. The presence of thou-
sands of gene transcripts in isolated RNA
are rapidly queried against cloned sources
of thousands of sequence-verified genes or
synthetic oligomers arrayed on small sur-
faces by nanotechnologies. The two major
platforms, cDNA and oligomer chip arrays,
each use easily renewable resources in con-
structing arrays that are greatly assisted by
robotics and automation. The sheer vol-
ume of DNA microarray data, or “high
information density,” its storage, analysis,
visual display, clustering, and relation to
other microarray data sets are major factors
that drive bioinformatics. 
By contrast, proteomics has a compara-
tively greater diversity of platforms that
reflect the many properties of proteins to
be measured in addition to its primary
sequence identity. Starting biological
material for proteomics studies often must
be freshly isolated by biochemical methods
from individual tissues. At present no sin-
gle proteomics platform can deliver an
information density of identified proteins
at a level comparable to DNA microarrays,
a fact that has hampered development of
bioinformatics in proteomics. However,
genomic sequence does not predict which
proteins interact and how, subcellular
localization, posttranslational processing
and modifications, or structure and topol-
ogy of the processed gene product.
Further, many signaling processes and
pathway cross-talk are not transcriptionally
dependent. The challenge in proteomics is
to take such unique properties of proteins
and to analyze them on a global scale.
Many established proteomic technologies
such as 2D gel-MS or multidimensional
liquid chromatography–MS currently
function extremely well as discovery-based
platforms capable of linking gene products
to function (Gagnon et al. 2002) or locali-
ties (Bruno et al. 2002) within the cell
(Jung et al. 2000). Recent technologic
advances make possible the identification
of hundreds of proteins in a single experi-
ment at high throughput commerical facil-
ities and through the release of new
technologies like ICAT (isotope-coded
affinity tags) (Gygi et al. 1999a) for tan-
dem MS analysis that permit simultaneous
detection of high abundance proteins and
low copy gene products alike (Hille et al.
2001; Honore 2001). 
HUPO has taken a platform neutral
stand, not favoring any particular method-
ology or device, but would like to move for-
ward in achieving its goal of mapping 5,000
human proteins. The exact human cell type
and environmental context are still under
consideration. However, the rapid devel-
opment of antibody microarrays (Fung et
al. 2001; Haab 2001) may represent an
attainable proteomics platform for high-
data density comparable to DNA microar-
rays by using highly parallel detection and
quantitation methods for specific proteins
from complex solutions. Thousands of
antibodies can be arrayed to recognize the
primary sequence for identifying specific
gene products from tissue lysates or biologi-
cal ﬂuids. In addition, it eventually will be
possible to array antibodies produced to
recognize speciﬁc posttranslational modiﬁ-
cations within a protein that are involved in
cell signaling processes critical to cellular
response to environmental stress and dis-
ease. High-quality antibody libraries as pro-
posed by HUPO will be fundamental in
building such arrays and may be the most
realistic means for dramatically increasing
the data density of proteomics studies
(Kodadek 2002). 
Integration of the
Transcriptome and Proteome
A major challenge for HUPO is develop-
ment of a strategy to integrate tissue tran-
script and protein expression datasets.
Protein abundance is generally related to
mRNA expression for various cellular
processes, but initial reports that compared
transcript expression and proteomic tech-
nologies have suggested that the levels of
mRNA and the corresponding gene prod-
uct were quite different (Gygi et al. 1999b).
While some biological conditions such as
rapid signaling-dependent responses are
well suited to a proteomic approach (Fessler
et al. 2002), the higher information density
of transcript analysis and ease of validation
by reverse transcriptase–polymerase chain
reaction are often viewed as primary reasons
for use of DNA microarrays in many appli-
cations. However, many scientists recognize
the advantage of bringing more informa-
tion to bear on biological problems and
have taken a systems biology approach
(Griffin et al. 2002) by using both DNA
microarrays and proteomics for better
hypothesis generation and for constructing
biochemical and regulatory pathways
(Ideker et al. 2001) in microorganisms
(Hecker and Engelmann 2000) and mam-
malian cells (Hanash 2001). The differing
and unique results stemming from tran-
script and proteomic technologies are often
regarded as complementary (Griffin et al.
2002) where differences between these
technologies can be resolved by further
validation and experimentation.
Because mRNA expression and protein
abundance data are signiﬁcantly more com-
plex and noisy than the underlying genomic
sequence information, some researchers
have proposed combining the expression
data from various data sets of different labo-
ratories into broad functional categories
such as composition, function, structure,
and localization (Greenbaum et al. 2002).
For example, by merging and scaling data
sets from yeast into a comprehensive refer-
ence set, a substantial agreement has been
observed in structural and functional cate-
gories (Greenbaum et al. 2002). Careful
consideration should be given to perform-
ing transcript and proteomic analysis on
common tissue from the inception of an
experimental study to integrate these data
sets. The development of algorithms that
analyze different proteomic and transcrip-
tomic datasets from various investigators in
the HUPO enterprise will be of great value
to the human health research community.
A targeted portion of HUPO research could
be encouraged for comparative proteomic
and transcript studies. 
Human Proteome and
Environmental Health
A major benefit of describing the human
proteome for human health will be its use
in biomarker development for disease.
There is great interest in discovering new
gene products or protein modiﬁcations that
might serve as biomarkers for cancer, heart
disease, neurologic disorders, and many
others. One aspect to be eventually exam-
ined by HUPO is the interaction and
effects of the environment on the proteome.
In particular, an understanding of xenobi-
otic exposures to toxicity and their contri-
bution to human disease are major areas of
environmental health research. Great strides
are expected in the coupling of protein
expression profiles of target tissues to spe-
ciﬁc cell signaling pathways, transcriptional
Toxicogenomics | HUPO and environmental health
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tems biology after environmental toxicant
exposure. Acquisition of affected and dis-
eased tissues from experimental animals is
relatively easy for use in biochemical and
molecular studies, but human organ and
tissue samples are much more difficult to
obtain. Blood, or its derivatives as serum or
plasma, is one of the most accessible body
fluids that might contain biomarkers
indicative of chemical exposure, toxicity,
and disease (Kodadek 2002). Transcript
analysis can be performed on whole blood
from extracted RNA of circulating lympho-
cytes and macrophages, and may be useful
for assessing pulmonary toxicant exposure,
some leukemias, and inflammatory condi-
tions. However, changes in blood transcript
levels may not always reﬂect toxic responses
for many organs and tissues after systemic
chemical exposure. 
The changing composition of the
serum proteome is more likely to contain
informative proteins directly related to
toxic responses and disease in the affected
organ or tissues (Kennedy 2001). Removal
of abundant serum proteins by immuno-
subtraction methods can greatly enrich for
disease-related proteins prior to separation
by 2D gels and identiﬁcation of proteins by
MS and has led to the discovery of new
serum biomarkers for gentamicin toxicity
(Kennedy 2001). Another innovation in
proteomics for discovering new serum bio-
markers involves the use of SELDI, or sur-
face-enhanced laser desorption ionization,
technology (Issaq et al. 2002). Serum pro-
teins are selectively bound to chemically
active surfaces on biochips and rapidly
scanned to obtain a spectrum of protein
masses by a modiﬁed MALDI-Tof (matrix
assisted laser desorption ionization–time of
flight) MS instrument. SELDI produces a
more accurate spectrum of protein masses
than gel electrophoresis, which is the more
conventional but less precise means of sep-
arating proteins by mass. Serum mass spec-
tra from different patient groups can be
normalized and compared for differences in
key clusters of protein masses after SELDI
analysis. By using training sets from known
normal and cancer patients and then ana-
lyzing SELDI data with sophisticated clus-
tering algorithms, discrete protein subsets
have been identified from SELDI analysis
of serum that are highly predictive of pre-
clinical ovarian cancer (Petricoin et al.
2002), prostate cancer (Adam et al. 2002),
and breast cancer (Li et al. 2002). Protein
identification from SELDI biochips is
actively being developed through use of
Tof-Tof (tandem MALDI MS) and other
tandem MS instruments specifically
adapted to analyze SELDI biochips
(Weinberger et al. 2002). Furthermore,
detection of protein adducts in blood and
serum may also serve as an indicator of
chemical exposure from reactive chemical
intermediates, toxicity from target organs,
and idiosyncratic responses to therapeutics
(Farmer 1999; Ju and Uetrecht 2002;
Liebler 2002). Proteomic analysis of the
human serum and plasma proteomes can
yield information on disease processes and
chemical exposure that specifically pertain
to environmental health.
In summary, the development of an
international agenda for research on the
human proteome has taken a great step for-
ward by the HUPO leadership. Although
there are many opportunities for techno-
logic development in proteomics, HUPO is
striving to serve as an international body
propelled by thoughtful biological questions
in biology, human disease, and environ-
mental health. The twin challenges are in
matching the scientific interest, expertise,
and funding toward accomplishing the
agendas outlined in the ﬁve areas of concen-
tration, and equally as important, in devel-
oping a vision that is well connected to the
large body of knowledge from transcript
expression studies and genomic technolo-
gies. The shared biological resources, proto-
cols, standards, and data from the HUPO
organization will greatly benefit environ-
mental health researchers seeking to move
from knowledge of the human proteome to
the next level for improving public health.
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